Table 2. Distribution of DXA Absorptiometry Parameters in AI-Naive and AI-Treated Patients With Breast Cancer.
| Characteristic | Group, No. (%) | P Valuea | |
|---|---|---|---|
| AI-Naive | AI-Treated | ||
| No. of patients | 361 (64.9) | 195 (35.1) | NA |
| DXA | |||
| Normal | 79 (21.9) | 24 (12.3) | .003 |
| Osteopenia/osteoporosis | 282 (78.1) | 171 (87.7) | |
| Morphometric vertebral fracture | |||
| Not present | 302 (83.7) | 142 (72.8) | .002 |
| Present | 59 (16.3) | 53 (27.2) | |
| Vertebral fracture grade | |||
| No | 302 (83.7) | 142 (72.8) | .006b |
| Mild | 31 (8.6) | 30 (15.4) | |
| Moderate/severe | 28 (7.8) | 23 (11.8) | |
| No. of vertebral fractures | |||
| 0 | 302 (83.7) | 142 (72.8) | <.001b |
| 1 | 44 (12.2) | 31 (15.9) | |
| ≥2 | 15 (4.2) | 22 (11.3) | |
| Lumbar spine, mean (95% CI) | |||
| BMD, g/cm2 | 0.897 (0.88 to 0.91) | 0.872 (0.85 to 0.88) | .09 |
| T score | −1.24 (−1.39 to −1.07) | −1.56 (−1.72 to −1.40) | .03 |
| Femoral neck, mean (95% CI) | |||
| BMD, g/cm2 | 0.69 (0.68 to 0.70) | 0.68 (0.67 to 0.69) | .46 |
| T score | −1.40 (−1.50 to −1.31) | −1.48 (−1.59 to −1.36) | .49 |
| Total hip, mean (95% CI) | |||
| BMD, g/cm2 | 0.82 (0.81 to 0.83) | 0.81 (0.80 to 0.83) | .72 |
| T score | −0.99 (−1.09 to −0.90) | −1.07 (−1.18 to −0.96) | .45 |
| Body mass, mean (95% CI), g | |||
| Lean | 39 580 (39 059 to 40 100) | 39 893 (39 200 to 40 585) | .50 |
| Fat | 24 754 (23 888 to 25 620) | 26 676 (25 402 to 27 951) | .03 |
| TBS, mean (95% CI)c | 1.26 (1.24 to 1.29) | 1.22 (1.19 to 1.25) | .006 |
Abbreviations: AI, aromatase inhibitor; BMD, bone mineral density; DXA, dual-energy x-ray; TBS, trabecular bone score.
a
P value from the Mann-Whitney test or the χ2 test as appropriate.
b
χ2 for trend test.
c
The TBS was assessed in a subset of 78 AI-naive and 50 AI-treated patients.